NASDAQ · Biotechnology · USD
CalciMedica, Inc. (CALC) Stock Analysis
CalciMedica, Inc. (CALC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CALC Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.10
- Previous Close
- $1.07
- Day's Range
- 1.07–1.20
- 52-Week Range
- 1.09–36.00
- Volume
- 103.06K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.10
Valuation
- Market Cap
- $7.65M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −6.85
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$29.56M
- Shares Outstanding
- 6.83M
- 1-Year Return
- −92.65%
Dividend and dates
- Avg Volume
- 75.60K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CALC closed at $1.15, −92.65% over 1 year.
CalciMedica, Inc. (CALC) has a market capitalization of $7.65M.
In fiscal 2025, CALC reported revenue of $0.00.
CALC Stock Return by Calendar Year
CalciMedica, Inc. (CALC) return since Jun 2023: what $10,000 became
- 1 year
- $10,000 $735
- −92.65%
- 3 years
- $10,000 $1,230
- −87.70%
- Since Jun 2023
- $10,000 $394
- −96.06%
If you had invested $10,000 in CalciMedica, Inc. (CALC) at the close on June 14, 2023, the earliest close on record here, it would have been worth $394 at the close on October 21, 2026: −96.06% in total, −61.88% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −96.51% |
| 2025 | +86.16% |
| 2024 | +23.78% |
| 2023 (partial year) | −51.03% |
As of October 21, 2026.
CALC Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$29.56M | — |
| 2024 | $0.00 | −$13.70M | — |
| 2023 | $0.00 | −$34.36M | — |
| 2022 | $0.00 | −$7.82M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$23.12M | −$29.56M | — |
| 2024 | $0.00 | — | −$24.20M | −$13.70M | — |
| 2023 | $0.00 | — | −$38.08M | −$34.36M | — |
| 2022 | $0.00 | — | −$14.19M | −$7.82M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
CalciMedica Announces Stephen Bardin To Resign As CFO Effective After Q3 2026 10-Q Filing
BenzingaCalciMedica Files Prospectus Supplement For Up To $25M At-The-Market Common Stock Offering
BenzingaCalciMedica Regains Nasdaq Compliance
BenzingaCalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
YahooCalciMedica Announces 1-For-5 Reverse Stock Split, Effective August 28
BenzingaGuggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9
Benzinga
All 8 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B